What proprietary (non-generic) treatments are available for NSCLC, and when were they licensed?
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Various proprietary treatments for NSCLC, including Pembrolizumab, Durvalumab, and Cemiplimab, have been licensed, primarily in 2025, targeting specific molecular and clinical patient profiles.
Fields of Study & Subjects
Lung Cancer Treatments and Mutations
Cancer Immunotherapy and Biomarkers
Lung Cancer Diagnosis and Treatment
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 30 March 2026
- Language
- EN